A prostate-specific membrane antigen (PSMA) can be used as a specific marker for tip-like ECs, which confirms the rationale for its use as a target for the diagnosis and treatment of non-prostate cancers as well [148]. This evidence concerns the gene FOLH1 and prostate cancer.